Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 8, 2007, Pages 514-517

  Wiseman, Gregory A ^a   Conti, Peter S ^b   Vo, Katie ^c   Schilder, Russell J ^d   Gordon, Leo I ^e   Emmanouilides, Christos ^f   Silverman, Dan H ^f   Witzig, Thomas E ^a   Darif, Mohamed ^c   Molina, Arturo ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c BIOGEN   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Indium 111 ibritumomab tiuxetan; Radioimmunoconjugates; Radioimmunotherapy; Radiopharmaceuticals

Indexed keywords

IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN IN 111; RADIOISOTOPE; RITUXIMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BLEEDING; BODY WEIGHT; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 35848931485     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.035     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Leonard JP. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology Am Soc Hematol Educ Program 2005; 1:335-339.
3. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23:8447-8452.
4. Zevalin* (ibritumomab tiuxetan) injection prescribing information. Cambridge, MA: Biogen Idec; 2006.
5. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793-3803.
6. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multi-center trial. Blood 2002; 99:4336-4342.
7. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
8. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-3269.
9. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103:4429-4431.
10. Witzig TE, Emmanouilides C, Molina A, et al. Yttrium-90 ibritumomab tiuxetan radioimmunomerapy (RIT) induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 2003; 22:597 (Abstract #2400).
11. Schilder R, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004; 19:478-481.
12. Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20:185-188.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244-1253.
14. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987-994.
15. Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood 2004; 104:1258-1265.
16. Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108:1504-1508.
17. Pan SY, Mao Y, Ugnat AM; Canadian Cancer Registries Epidemiology Research Group. Physical activity, obesity, energy intake, and the risk of non-Hodgkin's lymphoma: a population-based case-control study. Am J Epidemiol 2005; 162:1162-1173.
18. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348:1625-1638.
19. Tarella C, Caracciolo D, Gavarotti P, et al. Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplant 2000; 26:1185-1191.
20. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:1263-1270.
21. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 2006; 108:767a (Abstract #2714).
22. Zelenetz AD, Noy A, Pandit-Taskar N, et al. Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol 2006; 24(suppl):436s (Abstract #7560).
23. Hamlin PA, Moskowitz CH, Wegner BC, et al. Early safety and efficacy analysis of a phase II study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (Zevalin) for elderly high risk patients with untreated DLBCL. Blood 2005; 106:272a (Abstract #926).